1. Home
  2. VNDA

as 09-12-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Founded: 2002 Country:
United States
United States
Employees: N/A City: WASHINGTON
Market Cap: 249.4M IPO Year: 2006
Target Price: $16.50 AVG Volume (30 days): 404.6K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.14 EPS Growth: N/A
52 Week Low/High: $3.81 - $5.54 Next Earning Date: 11-05-2025
Revenue: $203,467,000 Revenue Growth: 11.78%
Revenue Growth (this year): 15.45% Revenue Growth (next year): 37.82%

VNDA Daily Stock ML Predictions

Share on Social Networks: